Olink Holding AB (publ) (OLK)
Company Description
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research.
Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.
The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services.
In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data.
Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden.
Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.
| Country | United States |
| Founded | 2004 |
| IPO Date | Mar 25, 2021 |
| Industry | Diagnostics & Research |
| Sector | Health Care |
| Employees | 416 |
Contact Details
Address:
Uppsala Science Park Uppsala 751 83 Sweden | |
| Phone | 46 1 84 44 39 70 |
Stock Details
| Ticker Symbol | OLK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $20.00 |
| CIK Code | 1835539 |
| ISIN Number | US6807101000 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Jon Heimer | Chief Executive Officer and Director |
| Oskar Hjelm | Chief Financial Officer |
| Fredrik Netzel | Chief Operating Officer |
| Dr. Ida Grundberg Ph.D. | Chief Scientific Officer |
| Jan Medina CFA | Vice President of Investor Relations and Capital Markets |
| Linda Ramirez-Eaves Esq. | General Counsel |
| Andrea Prander | Corporate Communications Manager |
| Johanna Isander | Chief People Officer |
| Rickard El Tarzi | Chief Strategy Officer |
| Carl Raimond | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 1, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 12, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Apr 7, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 7, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Apr 7, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Mar 17, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Mar 17, 2022 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] |
| Mar 7, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Feb 14, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |